Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pharmacoeconomic Evaluation of Long-term Effects on Health Recommended
October 11, 2004
- BUSINESS NEWS IN BRIEF
October 11, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
October 11, 2004
- Annual Business Results
October 11, 2004
- OTC NEWS IN BRIEF
October 11, 2004
- 1st Qtr Business Results
October 11, 2004
- MEDICAL DEVICE NEWS IN BRIEF
October 11, 2004
- Business Forecast
October 11, 2004
- DIAGNOSTIC NEWS IN BRIEF
October 11, 2004
- PMDA to Increase Number, Quality of Reviewers: Mr Miyajima
October 11, 2004
- Drug Costs Increase 0.6 Points to 22.2% in FY2003: Korosho Survey
October 11, 2004
- Korosho Explains Key Points of GVP, GQP GLs
October 11, 2004
- Social Security Benefits Rose 2.7% to \83.5 Trillion in FY2002
October 11, 2004
- So-net M3 Sets Up Physicians' Job Change Site for Drug Houses
October 4, 2004
- DIAGNOSTIC NEWS IN BRIEF
October 4, 2004
- REGULATORY NEWS IN BRIEF
October 4, 2004
- WORLD NEWS IN BRIEF
October 4, 2004
- BUSINESS NEWS IN BRIEF
October 4, 2004
- IITs Involve Insurance-related Problems
October 4, 2004
- NEW PRODUCTS
October 4, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…